Stella Diagnostics (Stella Diagnostics) Accounts Receivable : $0.00 Mil (As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Stella Diagnostics Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Stella Diagnostics's accounts receivables for the quarter that ended in Sep. 2023 was $0.00 Mil.

Accounts receivable can be measured by Days Sales Outstanding.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Stella Diagnostics's Net-Net Working Capital per share for the quarter that ended in Sep. 2023 was $-0.05.

Stella Diagnostics Accounts Receivable Historical Data

The historical data trend for Stella Diagnostics's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stella Diagnostics Accounts Receivable Chart

Stella Diagnostics Annual Data

Trend

Accounts Receivable

Stella Diagnostics Quarterly Data
	Sep22	Sep23
Accounts Receivable	-	-

Stella Diagnostics Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Stella Diagnostics Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Stella Diagnostics's Days Sales Outstanding for the quarter that ended in Sep. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Stella Diagnostics's accounts receivable are only considered to be worth 75% of book value:

Stella Diagnostics's Net-Net Working Capital Per Share for the quarter that ended in Sep. 2023 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(0.002	+	0.75 * 0	+	0.5 * 0	-	16.864
-	3.905	-	0)	/	401.6
=	-0.05

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

Stella Diagnostics Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Stella Diagnostics's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Stella Diagnostics (Stella Diagnostics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Stella Diagnostics Inc (OTCPK:SLDX) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

N/A

Address

50 West Broadway, Suite 300, Salt Lake City, UT, USA, 84104

Website

https://www.stelladx.com

Stella Diagnostics Inc is a molecular diagnostics-based organization focused on improving patient management strategies for people living with severe esophageal disease. It is developing first-line diagnostic tools that provide superior molecular information for providers as compared to the current standard screening protocols.